Literature DB >> 1768738

The antiviral activity of immune CD8+ T cells is dependent on interferon-gamma.

J Ruby1, I Ramshaw.   

Abstract

Vaccinia virus (VV) is a cytopathic virus that in normal mice exhibits only low virulence. However, when mice were treated throughout the course of the infection with mAb to IFN-gamma, the virus was lethal. The inability of these mice to clear the infection was not due to inhibition of effector T cell development since equally high numbers of cytotoxic T cells were generated in mAb- or control-treated mice. Instead, the data presented show that the defect was at the level of effector T cell activity. When immune CD8+ T cells were transferred to virus-infected recipients the infection was readily cleared. In contrast, effector cell function was totally blocked in mAb-treated recipients. We have considered these findings in view of our earlier observations that T cell deficient mice were able to resolve an otherwise lethal vv infection if infected with recombinant vv that encoded the genes for IL-2 or IFN-gamma. We propose a unifying concept such that antiviral T cells, which recognize infected cells in the context of class I MHC molecules, act to focus antiviral cytokines at the site of virus infection.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1768738

Source DB:  PubMed          Journal:  Lymphokine Cytokine Res        ISSN: 1056-5477


  34 in total

1.  Contributions of Fas-Fas ligand interactions to the pathogenesis of mouse hepatitis virus in the central nervous system.

Authors:  B Parra; M T Lin; S A Stohlman; C C Bergmann; R Atkinson; D R Hinton
Journal:  J Virol       Date:  2000-03       Impact factor: 5.103

2.  DNA immunization with minigenes: low frequency of memory cytotoxic T lymphocytes and inefficient antiviral protection are rectified by ubiquitination.

Authors:  F Rodriguez; L L An; S Harkins; J Zhang; M Yokoyama; G Widera; J T Fuller; C Kincaid; I L Campbell; J L Whitton
Journal:  J Virol       Date:  1998-06       Impact factor: 5.103

3.  Increased protection from vaccinia virus infection in mice genetically prone to lymphoproliferative disorders.

Authors:  Mina O Seedhom; Keisha S Mathurin; Sung-Kwon Kim; Raymond M Welsh
Journal:  J Virol       Date:  2012-03-21       Impact factor: 5.103

4.  CD70 and IFN-1 selectively induce eomesodermin or T-bet and synergize to promote CD8+ T-cell responses.

Authors:  Han Dong; Nathan A Franklin; Shane B Ritchea; Hideo Yagita; Martin J Glennie; Timothy N J Bullock
Journal:  Eur J Immunol       Date:  2015-11-06       Impact factor: 5.532

5.  Modulation by gamma interferon of antiviral cell-mediated immune responses in vivo.

Authors:  O Utermöhlen; A Dangel; A Tárnok; F Lehmann-Grube
Journal:  J Virol       Date:  1996-03       Impact factor: 5.103

6.  Gamma interferon is critical for resistance to Theiler's virus-induced demyelination.

Authors:  M Rodriguez; K Pavelko; R L Coffman
Journal:  J Virol       Date:  1995-11       Impact factor: 5.103

7.  Importance of interferons in recovery from mousepox.

Authors:  G Karupiah; T N Fredrickson; K L Holmes; L H Khairallah; R M Buller
Journal:  J Virol       Date:  1993-07       Impact factor: 5.103

Review 8.  What is the role of alternate splicing in antigen presentation by major histocompatibility complex class I molecules?

Authors:  Alan Belicha-Villanueva; Jennifer Blickwedehl; Sarah McEvoy; Michelle Golding; Sandra O Gollnick; Naveen Bangia
Journal:  Immunol Res       Date:  2010-03       Impact factor: 2.829

9.  Effects of virally expressed interleukin-10 on vaccinia virus infection in mice.

Authors:  M G Kurilla; S Swaminathan; R M Welsh; E Kieff; R R Brutkiewicz
Journal:  J Virol       Date:  1993-12       Impact factor: 5.103

10.  Helminth infection results in decreased virus-specific CD8+ cytotoxic T-cell and Th1 cytokine responses as well as delayed virus clearance.

Authors:  J K Actor; M Shirai; M C Kullberg; R M Buller; A Sher; J A Berzofsky
Journal:  Proc Natl Acad Sci U S A       Date:  1993-02-01       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.